A Study Comparing Oxymetazoline 1% Cream to RHOFADE

NCT05148689 PHASE1 COMPLETED

randomized, double-blind, placebo controlled

Details

Lead sponsor	Sun Pharmaceutical Industries, Inc.
Phase	PHASE1
Status	COMPLETED
Enrolment	82
Start date	Fri Feb 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Bioequivalence

Interventions

• Oxymetazoline hydrochloride Cream, 1%
• Rhofade™ (oxymetazoline) cream, 1%
• Placebo

Countries

United States